Thursday 23 October 2014, 12.30PM to 1.30pm
Speaker(s): Dennis Raisch PhD, Professor of Pharmacy at the University of New Mexico Health Sciences Center
Abstract: The global market for biologics was $170 billion in 2012, accounting for 19% of the pharmaceutical market. Once patent expiration is reached for a reference biologic, the use of a biosimilar can decrease costs by 25-50%. Although the Food and Drug Administration (FDA) and European Medicines Agency (EMA) have regulations for marketing approval of biosimilars, equivalence studies are conducted among a relatively small number of patients compared to a reference biologic license approval. However, the regulator may also require post-marketing studies. To determine the relative importance of cost savings and post-marketing studies, we conducted an MCDA for the adoption of biosimilars. In addition we assessed differences in perspectives of different stakeholders (oncologists, pharmacist, health payer, regulator/policy maker) and country of residence (US, Netherlands, Germany). This presentation will describe current issues surrounding the adoption of biosimilars, describe the MCDA study, and present our initial findings.
Location: Alcuin A Block A019/020
Who to contact
For more information on these seminars, contact:
- Ana Duarte
ana.duarte@york.ac.uk- James Lomas
james.lomas@york.ac.uk
Economic evaluation seminar dates
- 10 December 2014
Claire Hulme, Professor of Health Economics, University of Leeds